Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

Summary

This clinical trial aims to evaluate the efficacy and safety of pembrolizumab in the first-line treatment of advanced NSCLC complicated with COPD and its influence on the course of COPD, so as to provide prospective clinical evidence for immunotherapy of NSCLC complicated with COPD in China and to guide clinical application.

Timeline

Start

2022-10-10

Primary completion

2023-12-12

Completion

2024-12-12

Publications

• Dong W, Yin Y, Liu B, Jiang Y, Wang L, Shi D, Qin J. Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial. Front Oncol. 2024 Mar 7;14:1179232. doi: 10.3389/fonc.2024.1179232. eCollection 2024.

Drugs

Indications